Curanex Pharmaceuticals (CURX) Net Cash Flow (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Net Cash Flow came in at -$857404.0 in Q4 2025, down 798.49% YoY from $122750.7 in Q4 2024, and down 114.99% on a QoQ basis from $5.7 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Net Cash Flow (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Net Cash Flow data on file, last reported at -$857404.0 in Q4 2025.
- Quarterly Net Cash Flow fell 798.49% year-over-year to -$857404.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.8 million (changed N/A YoY) and the FY2025 annual result came in at $4.8 million, up 6373.32% from the prior year.
- Net Cash Flow fell to -$857404.0 in Q4 2025, from $5.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $5.7 million in Q3 2025 to a low of -$857404.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 225.59 Mn |
| 10 | Curanex Pharmaceuticals | 6.07 Mn | 1.07 Mn | - | -857,404.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -857,404.00 |
| Dec 31, 2025 | -857,404.00 |
| Sep 30, 2025 | 5.72 Mn |
| Sep 30, 2025 | 5.72 Mn |
| Dec 31, 2024 | -95,427.00 |
| Dec 31, 2024 | -95,427.00 |
| Sep 30, 2024 | -129,943.00 |
| Sep 30, 2024 | -129,943.00 |